Macrogen Becomes First CRO to Adopt 10x Genomics’ Atera Spatial Platform

Macrogen, a global CRO, along with its U.S. subsidiary Psomagen, has committed to deploying multiple Atera instruments, becoming the first global service provider to adopt the platform. The move signals early traction for Atera in outsourced research environments, where demand for scalable and standardized spatial biology workflows continues to grow.

The adoption is intended to support high-throughput spatial transcriptomics programs, enabling CRO-led studies that require comprehensive gene expression analysis within intact tissue samples. According to the company, the platform is designed to remove traditional trade-offs between sensitivity, scale, and gene coverage, making it suitable for large, multi-sample research programs.

The investment reflects increasing demand from pharmaceutical and biotechnology companies for advanced spatial analysis tools in drug discovery and translational research. CROs are increasingly integrating such platforms to support biomarker discovery, patient stratification, and precision medicine initiatives at scale.